Expertise in
30
conditions

Dr. Mark V. Mishra

Radiation Oncology | Radiology
University Of Maryland Radiation Oncology Associates PA
22 S Green St, 
Baltimore, MD 
 (2377.3 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
30
conditions
University Of Maryland Radiation Oncology Associates PA
22 S Green St, 
Baltimore, MD 
 (2377.3 mi)
OverviewInsuranceLocationsClinical Research

Overview

Mark Mishra is a Radiation Oncologist and a Radiologist in Baltimore, Maryland. Dr. Mishra is highly rated in 30 conditions, according to our data. His top areas of expertise are Astrocytoma, Metastatic Brain Tumor, Meningioma, Posterior Fossa Tumor, and Prostatectomy. Dr. Mishra is currently accepting new patients.

His clinical research consists of co-authoring 108 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Radiology
Licenses
Internal Medicine in IL
Hospital Affiliations
University Of Maryland Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

UNIVERSITY OF MARYLAND RADIATION ONCOLOGY ASSOCIATES PA
22 S Green St, Baltimore, MD 21201
Other Locations
MARYLAND PROTON TREATMENT CENTER, LLC
850 W Baltimore St, Baltimore, MD 21201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: January 22, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Other, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Identifying Patient-relevant Adverse Events Following Prostate Radiotherapy
Identifying Patient-relevant Adverse Events Following Prostate Radiotherapy
Enrollment Status: Completed
Publish Date: November 05, 2024
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Other, Drug, Radiation
Study Drug: Memantine
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2024
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2024
Intervention Type: Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
Randomized Pilot Study of Six Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Patients With Newly Diagnosed MGMT Methylated Glioblastoma (GBM) Following Standard Concurrent Radiation and TMZ
Randomized Pilot Study of Six Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Patients With Newly Diagnosed MGMT Methylated Glioblastoma (GBM) Following Standard Concurrent Radiation and TMZ
Enrollment Status: Withdrawn
Publish Date: August 10, 2022
Intervention Type: Other
Neoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients With Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study
Neoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients With Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study
Enrollment Status: Completed
Publish Date: August 19, 2019
Intervention Type: Drug, Other
Study Phase: Early Phase 1
View 14 Less Clinical Trials

108 Total Publications

The Use of External Beam Radiation Therapy for Heterotopic Ossification Prophylaxis After Surgical Fixation of Acetabular Fractures: A Randomized Controlled Trial.
The Use of External Beam Radiation Therapy for Heterotopic Ossification Prophylaxis After Surgical Fixation of Acetabular Fractures: A Randomized Controlled Trial.
Journal: Journal of orthopaedic trauma
Published: October 27, 2024
Similar Doctors
Expertise in
31
conditions
Dr. Lawrence R. Kleinberg
Radiation Oncology
Expertise in
31
conditions
Dr. Lawrence R. Kleinberg
Radiation Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (1.9 mi)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lawrence Kleinberg is a Radiation Oncologist in Baltimore, Maryland. Dr. Kleinberg is highly rated in 31 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Glioma, and Gamma Knife Radiosurgery. Dr. Kleinberg is currently accepting new patients.

Expertise in
18
conditions
Dr. Russell K. Hales
Radiation Oncology
Expertise in
18
conditions
Dr. Russell K. Hales
Radiation Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (1.9 mi)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Russell Hales is a Radiation Oncologist in Baltimore, Maryland. Dr. Hales is highly rated in 18 conditions, according to our data. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Orchiectomy, and Endoscopy. Dr. Hales is currently accepting new patients.

Expertise in
31
conditions
Dr. Ana P. Kiess
Radiation Oncology | Radiology
Expertise in
31
conditions
Dr. Ana P. Kiess
Radiation Oncology | Radiology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (1.9 mi)
410-955-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ana Kiess is a Radiation Oncologist and a Radiologist in Baltimore, Maryland. Dr. Kiess is highly rated in 31 conditions, according to our data. Her top areas of expertise are Prostate Cancer, Laryngeal Cancer, Throat Cancer, Gastrostomy, and Adenoidectomy. Dr. Kiess is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile